Sigma (ASX:SIG) forecasts 10% drop in FY 2022 EBITDA

Be the First to Comment Read

Sigma (ASX:SIG) forecasts 10% drop in FY 2022 EBITDA

Sigma forecasts a 10% drop in underlying Ebitda in FY 2022, Sigma Healthcare Limited, FY 2022
Image source: © Narajana | Megapixl.com

Highlights

  • Sigma Healthcare Limited (ASX:SIG) was instrumental in immunising Australia.
  • Sigma anticipates FY22 Underlying EBITDA to be down around 10% from FY21 after the first 10 months of the fiscal year.
  • Sigma estimates that the setback would cost it between AU$25 million and AU$30 million in one-time costs and that this might affect when its net debt reaches its peak.

Drug distributor Sigma Healthcare Limited (ASX: SIG) was instrumental in immunising Australia. Covid-19 plagued Australia, and many businesses suffered as a result. Sigma stepped forward at the time to vaccinate Australians so that business and the economy would not be disrupted.

Unfortunately, by the end of 2021, Sigma's fate had been written by another storey. As a result, the Company has forecasted a drop in EBITDA.

Let's take a look at Sigma's EBITDA forecast.

Recent Article: Is Sigma proposal superior in API bidding war?

What is Sigma's EBITDA prediction?

Sigma revealed today that it anticipates FY22 Underlying EBITDA to be down around 10% from FY21 after the first 10 months of the fiscal year.

Jeff Sells, Interim Chief Financial Officer, said:

What’s next?

Sigma estimated that the setback would cost it between AU$25 million and AU$30 million in one-time costs and that this might affect when its net debt reaches its peak.

Recent Article: 5 high performing ASX dividend paying healthcare stocks

Disclaimer

Speak your Mind

Featured Articles

Ad
kalkine logo

GET A FREE STOCK REPORT

Top Penny Picks under 20 Cents to Fit Your Pocket! Get Exclusive Report on Penny Stocks For FREE Now.

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK